CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CVM shares have decreased by 65.0% and is now trading at $3.41. View which stocks have been most impacted by COVID-19.
Full Answer
How much is a CVM stock worth?
Apr 05, 2022 · The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -37.34% during the next 3 months and, with a 90% probability hold a price between $2.00 and $2.71 at the end of this 3-month period. Do note, that if the stock price manages to stay at …
Will Cel-Sci (CVM) outperform or underperform the S&P 500?
Jul 08, 2021 · At last check, CEL-SCI Corporation shares were down -5.65% to trade at $8.19 in pre-market trading. During Wednesday’s trading session, CEL-SCI stock rose 8.50% to $8.68. CVM stock volume was 7.55 million shares, compared to the one million shares averaged over the past 50 days. In the past week, CVM shares have moved down by -32.35%.
Is Ooi driving the CVM up?
Jun 28, 2021 · Here's the news that has sent CVM stock lower today. Today, investors in Cel-Sci (NYSEMKT: CVM) and CVM stock are seeing a very red day. Indeed, the fact that shares of CVM stock are down nearly ...
Does CVM stock go up?
The CEL-SCI Corporation stock price gained 4.56% on the last trading day (Friday, 8th Apr 2022), rising from $3.73 to $3.90....Predicted Opening Price for CEL-SCI Corporation of Monday, April 11, 2022.Fair opening price April 11, 2022Current price$3.87$3.90 (Overvalued)
Is CVM shorted?
Short Shares Availability This table shows the number of shares of US:CVM available to be shorted at a leading prime brokerage. It is not the total number of shares available to short, nor is it the short interest. It does not include data from other brokers or dark pools.
Why is Cel-Sci stock dropping?
The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
What happened CEL-SCI?
CEL-SCI plummets 43% after phase 3 immunotherapy data misses primary endpoint. Shares of CEL-SCI Corp. (NYSE:CVM) have plummeted 43% after phase 3 data on its Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for head and neck cancer.Jun 28, 2021
Will Cel-Sci get FDA approval?
The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval....NEWS RELEASE8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.comCOMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460Jul 7, 2021
Will multikine get FDA approval?
Multikine has not been licensed or approved by the FDA or by any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
What is multikine?
A mixture of different immune molecules, potentially simulating the natural immune system: Multikine is composed of a defined mixture of naturally occurring molecules which in early-phase studies have been reported to be biologically/immunologically active.
How has CEL-SCI's stock price been impacted by COVID-19?
CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since th...
When is CEL-SCI's next earnings date?
CEL-SCI is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for CEL-SCI .
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Wednesday, December, 22nd. The company reported ($0.19) earnings per share...
When did CEL-SCI's stock split? How did CEL-SCI's stock split work?
CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares own...
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the following people: Mr. Geert R. Kersten , CEO, Principal Accounting & Financial Officer, Treasurer and Dire...
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Sangamo Therapeutics (SGMO) , Atara Biotherapeutics (ATRA) , Replimune Group (REPL) , Agenus...
What other stocks do shareholders of CEL-SCI own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX)...
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
Who are CEL-SCI's major shareholders?
CEL-SCI's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (7.79%), Blac...
Here are some highlights of the letter
As a result of CVM’s Multikine immunotherapy, the world’s largest Phase 3 study of newly diagnosed advanced primary head and neck cancer demonstrated a statistically significant survival benefit of 14.1% after receiving surgery and radiotherapy.
How CVM is planning to move forward?
CEL-SCI (CVM) announced results from a Phase 3 study on June 28, 2021, which showed that Multikine achieved all of the protocol requirements stated in the study protocol in patients receiving surgery and radiation as their standard therapies.
Pre-Market Cues: 45 Stocks Roaring for Change On November 16th
CBAK Energy Technology Inc. (CBAT) stock soared 51.22% to $9.3 in pre-market trading. Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) shares are trading
How much cash does Cel Sci have?
News flash,, you can’t take it with you and studies show a very high percentage of us will get some sort of cancer in our lifetime. Cel Sci has about 43 million dollars cash on hand going into the NDA. The Facility is at completion including the expansion. Most of the major job position have been filled.
Is Merck's immunotherapy approved?
The Food and Drug Administration won't yet approve Merck & Co.'s immunotherapy Keytruda for a tough-to-treat form of early-stage breast cancer, choosing instead to wait for the drugmaker to accrue results from an ongoing Phase 3 trial.
Does MK save life?
Since the FDA has a Precedence in approving life saving drugs on an emergency use basis. And MK has proven to save life’s with no toxicity. Then Cel Sci should apply for emergency use as soon as possible. Many lives depend on it.
When did the 1-25 reverse split happen?
The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.
Is Marketbeat better than CEL-SCI?
What stocks does MarketBeat like better than CEL-SCI? Wall Street analysts have given CEL-SCI a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CEL-SCI wasn't one of them.